For decades, the standard treatment for these potentially ... benralizumab could become the first new therapy approved for eosinophilic exacerbations of asthma and COPD in over 50 years.

Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

A recent trial showed that nicotinamide riboside supplementation might reduce airway inflammation in patients with COPD who ...

Pulmonary fibrosis in patients with COVID-19 tends to resolve, while idiopathic pulmonary fibrosis always progresses.

New Study Shows Promising Results for COPD Treatment Nov. 20, 2024 — A new study shows that a form of vitamin B3 can reduce lung inflammation in COPD patients. The researchers hope it will pave ...

Here, Tan and other experts in the field describe how this new understanding of inflammation is informing treatment. And it's ...

Researchers have identified new lung function and blood test cutoffs to improve timely chronic hypercapnia management in ...

Explore strategies for controlling COPD and improving health, with a focus on management and lifestyle changes.

After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

Multiple chemicals in cigarette smoke and e-cigarettes alter the function of a key type of lung immune cell. Cigarette ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...